Edodekin alfa

DB15631InvestigationalProtein Based Therapies

Edodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or...

Mechanism: Pharmacologically active on Interleukin-12 receptor subunit beta-1 and Interleukin-12 receptor subunit beta-2
Curator reviewed
Also known as: Human il-12 (recombinant) · Interleukin 12 (human) · Interleukin-12, human · Recombinant Human Interleukin-12 · Recombinant interleukin-12
Code names: NM-IL-12 · RO-24-7472 · RO 24-7472/000

Resolves to

Compound

UNII31Z82G8ME1CAS187348-17-0

Clinical / RWD

RxNorm1318050

Targets

P42701IL12RB1Q99665IL12RB2

What you can answer from here — as of July 11, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

35Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Edodekin alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account